March 30 () - Merck's oral drug reduced bad cholesterol by up to ‌64.6% in a late-stage trial, ‌the drugmaker said on Monday, ...

By Christy Santhosh March 30 (Reuters) - Drugmaker Merck said on Monday its oral drug met the main goal of meaningfully ...

In an R&D collaboration worth as much as $838 million, Merck will lean on Infinimmune to discover immune cell-directed ...

Merck is eyeing a quick review for its lipid-lowering drug candidate enlicitide, which in December was awarded a Commissioner ...

Merck & Co. has lifted the lid on the third successful phase 3 trial of its PCSK9 inhibitor, showing the edge the ...

Merck & Co. is rounding out its March deal flurry with an antibody discovery pact that could be worth as much as $838 million ...

March 31 (Reuters) - Biotech firm Infinimmune said on Tuesday it has entered into a deal with Merck, that could be worth up ...

The lack of a dose-response effect could be due to the high number of dropouts in the higher-dose Winrevair arm and the relatively small study population, a discussant for Merck explained.

If consummated, the deal would hand Merck a treatment that could challenge Novartis’ fast-selling Scemblix. But the low ...

Merck is bulking up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.

Merck has struck a $5.7bn deal to buy Terns Pharmaceuticals, a US biotech developing treatments for a rare form of blood and ...

>40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is developing ...